Table 3 Characteristics of HSCT in thalassemia patients with offspring undergoing allogeneic HSCT
Patient | Age at transplant | Date of transplant | Sex | Donor Sex | Donor Type | Source of Stem cells | aGVHD | cGVHD | Conditioning |
|---|---|---|---|---|---|---|---|---|---|
1 | 8 | 1991 | Male | Male | HLA-identical sibling | BM | – | Mild Limited | Cyclophosphamide/busulfan |
2 | 19 | 2008 | Male | Male | HLA-identical sibling | Mesenchymal + PB | – | Moderate Extensive | Fludarabine/busulfan ATG |
3 | 18 | 2009 | Male | Male | HLA-identical sibling | Mesenchymal + PB | Grade 1 | – | Fludarabine/busulfan ATG |
4 | 26 | 2005 | Male | Male | HLA-identical sibling | BM | – | Mild Limited | Fludarabine/busulfan |
5 | 22 | 2008 | Male | Male | HLA-identical sibling | Mesenchymal + PB | – | – | Fludarabine/busulfan ATG |